Defence Therapeutics Inc.
DTC
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -29.24% | 54.85% | -0.05% | 83.90% | -273.32% |
| Total Depreciation and Amortization | -2.31% | -63.38% | 112.57% | -- | -100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 44.84% | 20.02% | 54.69% | -98.85% | 8,453.01% |
| Change in Net Operating Assets | -128.60% | -19.16% | 126.23% | -- | -100.00% |
| Cash from Operations | -844.93% | 116.48% | 44.28% | -- | 100.00% |
| Capital Expenditure | -- | -- | 107.82% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 107.82% | -- | 100.00% |
| Total Debt Issued | -100.00% | -70.00% | -- | -- | -- |
| Total Debt Repaid | -365.83% | -256.41% | 0.00% | -- | 100.00% |
| Issuance of Common Stock | -- | -- | -98.97% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | 5,032.98% | -122.49% | -95.72% | -- | 100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -100.91% | 116.34% | -375.93% | -- | 100.00% |